Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D.

EJNMMI research·2026
Same author

Cell-Based Immunization Combined with Single-Round Cell Panning Enables Discovery of PSMA-Targeting Nanobodies from Phage Display Libraries.

Biomolecules·2026
Same author

Head-to-head comparison of [<sup>177</sup>Lu]Lu-FAP-2286 and [<sup>161</sup>Tb]Tb-FAP-2286 efficacy in a PDAC mouse model.

EJNMMI research·2026
Same author

Phase I Clinical Study with the GRPR-Antagonist [<sup>99m</sup>Tc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?

Pharmaceutics·2025
Same author

The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [<sup>99m</sup>Tc]Tc-DB8.

Pharmaceutics·2025

Related Experiment Video

Updated: Oct 12, 2025

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB
08:33

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB

Published on: June 28, 2011

13.1K

Radiolabeled Bombesin Analogs.

Rosalba Mansi1, Berthold A Nock2, Simone U Dalm3

  • 1Division of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine University Hospital Basel, 4031 Basel, Switzerland.

Cancers
|November 27, 2021
PubMed
Summary
This summary is machine-generated.

Gastrin-releasing peptide receptor (GRPR) targeted therapies show promise for prostate and breast cancers. Ongoing research aims to improve diagnostic and therapeutic molecular tools by addressing limitations of current GRPR agonists and antagonists.

Keywords:
cancer theranosticsgastrin-releasing peptide receptorradiolabeled bombesin

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

7.8K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.1K

Related Experiment Videos

Last Updated: Oct 12, 2025

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB
08:33

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB

Published on: June 28, 2011

13.1K
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

7.8K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.1K

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate and breast cancers.
  • GRPR targeted therapies utilize peptide analogs to deliver diagnostic or therapeutic radionuclides to tumors.
  • Early GRPR agonists faced challenges including low metabolic stability and adverse effects.

Purpose of the Study:

  • To review the development and clinical application of GRPR-targeted diagnostic and therapeutic agents.
  • To discuss the evolution from GRPR agonists to antagonists and their respective outcomes.
  • To highlight current challenges and future directions in optimizing GRPR-targeted cancer therapies.

Main Methods:

  • Review of preclinical and clinical studies on GRPR-targeted peptide analogs.
  • Analysis of the development of GRPR agonists and antagonists.
  • Evaluation of factors influencing GRPR expression and therapeutic efficacy.

Main Results:

  • GRPR agonists showed initial promise but were limited by poor metabolic stability and off-target accumulation.
  • GRPR antagonists demonstrated improved safety and pharmacokinetic profiles.
  • Clinical trials revealed promising outcomes but also highlighted variability in GRPR expression impacting treatment effectiveness.

Conclusions:

  • GRPR-targeted therapies represent a significant advancement in molecular oncology.
  • Further research is needed to overcome limitations related to GRPR expression variability and optimize therapeutic strategies.
  • Continued interdisciplinary collaboration is crucial for developing advanced, safe, and effective GRPR-targeted molecular tools for cancer treatment.